XIAOHONG JIANG
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care BALTIMORE, MD NPI 1063137263
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care MD NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$2,338.24
- Category: General Payments
- Program years: PY2022–2024
- Record count: 75
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,576.99 across 47 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,033.21 | 41 |
| Long term medical supply or device loan | $398.80 | 4 |
| Education | $144.98 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $477.50 | 8 |
| Acerta Pharma LLC | $137.78 | 5 |
| Incyte Corporation | $99.64 | 2 |
| Janssen Biotech, Inc. | $80.74 | 2 |
| Merck Sharp & Dohme Corporation | $76.87 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $69.99 | 1 |
| Regeneron Healthcare Solutions, Inc. | $65.17 | 3 |
| ABBVIE INC. | $62.87 | 2 |
| BeiGene USA, Inc. | $58.64 | 2 |
| E.R. Squibb & Sons, L.L.C. | $54.33 | 2 |
| GlaxoSmithKline, LLC. | $50.45 | 2 |
| Exelixis Inc. | $38.54 | 1 |
| Gilead Sciences, Inc. | $33.51 | 1 |
| Alnylam Pharmaceuticals Inc. | $32.24 | 2 |
| TAIHO ONCOLOGY, INC. | $29.11 | 1 |
| Lilly USA, LLC | $28.21 | 1 |
| Pharmacosmos Therapeutics Inc. | $27.72 | 1 |
| Mirati Therapeutics, Inc. | $25.76 | 1 |
| Alexion Pharmaceuticals, Inc. | $24.33 | 1 |
| Ethicon US, LLC | $22.32 | 1 |
| Daiichi Sankyo Inc. | $22.23 | 1 |
| Azurity Pharmaceuticals, Inc. | $21.67 | 1 |
| ADC Therapeutics America, Inc. | $21.16 | 1 |
| Astellas Pharma US Inc | $16.21 | 1 |
By program year
Records — PY2024 (47)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.